Full-thickness macular hole formation following anti-VEGF injections for neovascular age-related macular degeneration
Received 22 February 2017
Accepted for publication 6 April 2017
Published 26 May 2017 Volume 2017:12 Pages 911—915
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Colin Mak
Peer reviewer comments 2
Editor who approved publication: Dr Richard Walker
Stamatina A Kabanarou,1 Tina Xirou,1 George Mangouritsas,1 Christina Garnavou-Xirou,2 Eirini Boutouri,1 Ilias Gkizis,1 Irini Chatziralli3
1Retina Department, Korgialeneio Benakeio, Hellenic Red Cross Hospital, Athens, Greece; 2Retina Department, King’s College Hospital, London, UK; 32nd Department of Ophthalmology, University of Athens, Athens, Greece
Purpose: Macular hole (MH) is part of a group of age-related degenerative diseases characterized by pathology of vitreomacular interface. Similarly, neovascular age-related macular degeneration (nAMD) affects older patients and is a leading cause of irreversible visual loss. The purpose of this case series is to describe the development of full-thickness MH in patients with nAMD, following antivascular endothelial growth factor (anti-VEGF) treatment.
Methods: Participants in this case series were four patients with nAMD, who received anti-VEGF injections with variable therapeutic response to treatment. Patients were examined at baseline (when AMD was diagnosed) and monthly thereafter. The examination included visual acuity measurement, slit-lamp biomicroscopy, and optical coherence tomography.
Results: All patients were found to develop full-thickness MH within 1–4 months after the last anti-VEGF injection, even in the absence of pre-existing vitreomacular interface abnormalities in some cases. The median number of injections before the MH formation was 3.
Conclusion: MH formation may represent an adverse effect of anti-VEGF treatment in patients with nAMD and could be also coexisting pathology with nAMD in older individuals.
Keywords: macular hole, age-related macular degeneration, anti-VEGF
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]